Desk›Healthcare› Sun Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd
BSE 524715 · NSE SUNPHARMA · ISIN INE044A01036 · Group A · Active
Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
₹1,900.50
-0.03%
BSE close, 28 August 2026
₹455,982.87 cr
239.9 cr shares · Large cap
₹205,016.28 cr
as published
152.3× · 19.33×
EPS ₹12.48 · BV ₹98.32
20,754.64 / 2,623.42
₹ cr, as filed
33
11 selected · 33%
Reg 30
Sch. III Part A
Price 52-week, BSE
| Against 52-week high | -7.2% |
|---|---|
| Against 52-week low | +22.8% |
| Day change | -0.03% |
| Size band | Large cap |
| Index membership | NIFTY 50, NIFTY 500 |
Valuation as published by BSE
| Earnings per share | ₹12.48 |
|---|---|
| Price / earnings | 152.28× |
| Price / book | 19.33× |
| Book value — derived, price ÷ P/B | ₹98.32 |
| Return on equity | 12.69% |
| Operating margin | 36.11% |
| Net margin | 19.42% |
Consistency check
- P/B ÷ P/E, which must equal ROE
- 12.69%
- ROE as published
- 12.69%
Results ₹ crore, as filed
RevenueNet profit one scale across all three periods, ₹ crore
| Period | Revenue ₹cr | Net profit ₹cr | EPS ₹ | OPM | NPM |
|---|---|---|---|---|---|
| Jun-26 · Q | 5,741.13 | 1,115.14 | 4.60 | 36.11% | 19.42% |
| Mar-26 · Q | 4,923.88 | 608.70 | 2.50 | 28.27% | 12.36% |
| FY25-26 | 20,754.64 | 2,623.42 | 10.90 | 29.17% | 12.64% |
Quarter on quarter
- Revenue, quarter on quarter
- +16.6%
- Net profit, quarter on quarter
- +83.2%
- Operating margin, quarter on quarter
- +784 bps
Disclosure profile 33 filings in the window
| Tag | Filings |
|---|---|
| Selected | |
| Press Release | 6 |
| Credit Rating | 2 |
| Concall Transcript | 1 |
| Investor Presentation | 1 |
| Results | 1 |
| Selected sub-total | 11 |
| Procedural | |
| General | 10 |
| Newspaper Publication | 4 |
| Analyst / Investor Meet | 3 |
| Postal Ballot | 2 |
| AGM / EGM | 1 |
| Board Meeting | 1 |
| Trading Window | 1 |
| Procedural sub-total | 22 |
| Total | 33 |
Disclosure regime
LODR Reg 30
Read with Schedule III Part A. An equity filer in BSE Group A, so the Regulation 30 disclosure framework and the Schedule III event list both apply.
Filing rhythm · 93 trading days
33 filings · 11 selected · busiest 2026-07-31
Filing rhythm · the twelve most recent
2026-09-112026-10-07
SelectedProcedural
Filings
33 in the window · 14 earlier on record
-
7 October 2026 ·
Board Meeting Intimation for Consideration And Approval Of The Issuance Of Listed, Rated, Unsecured, Redeemable, Non-Convertible Debentures
Sun Pharmaceutical Industries Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/10/2026 ,inter alia, to consider and approve the issuance ....
Board Meeting / Board Meeting View filing →
-
6 October 2026 ·
Press Release / Media Release
Press Release
Company Update / Press Release / Media Release View filing →
-
2 October 2026 ·
Newspaper Publication
Newspaper publication about Postal Ballot/E-voting October 2026
Company Update / Newspaper Publication View filing →
-
1 October 2026 ·
Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
Notice of Postal ballot October 2026
AGM/EGM / Postal Ballot View filing →
-
1 October 2026 ·
Press Release / Media Release
Press Release is enclosed
Company Update / Press Release / Media Release View filing →
-
30 September 2026 ·
Newspaper Publication
Newspaper publication about the opening of Special Window for transfer of physical shares
Company Update / Newspaper Publication View filing →
-
29 September 2026 ·
-
28 September 2026 ·
Completion And Result Of Postal Ballot Dated 25 August 2026
Completion and Result of Postal Ballot dated 25 August 2026
Company Update / General View filing →
-
28 September 2026 ·
Press Release / Media Release
Press Release for lerodalcibep licensing agreement
Company Update / Press Release / Media Release View filing →
-
25 September 2026 ·
Closure of Trading Window
Trading Window closure
Insider Trading / SAST / Closure of Trading Window View filing →
-
22 September 2026 ·
Investor Presentation
Investor Presentation Sept-2026
Company Update / Investor Presentation View filing →
-
11 September 2026 ·
-
9 September 2026 ·
Inc orporation Of A Subsidiary Company
Inc orporation of wholly owned subsidiary of the Company in the International Financial Services Centre at GIFT City, Gandhinagar, Gujarat, India
Company Update / General View filing →
-
8 September 2026 ·
-
3 September 2026 ·
Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst/Institutional Investor Meeting
Company Update / Analyst / Investor Meet View filing →
-
1 September 2026 ·
Press Release / Media Release
Sun Pharma participates in White House Signing Ceremony highlighting U.S. Medicines Pricing and Access Commitments
Company Update / Press Release / Media Release View filing →
-
26 August 2026 ·
Newspaper Publication
Newspaper Advertisements about Postal Ballot/E-voting
Company Update / Newspaper Publication View filing →
-
25 August 2026 ·
Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
Notice of Postal Ballot/E-voting
AGM/EGM / Postal Ballot View filing →
-
25 August 2026 ·
Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst/Institutional Investor Meeting
Company Update / Analyst / Investor Meet View filing →
-
17 August 2026 ·
Update On Lipitor Antitrust Litigation
Update on Lipitor Antitrust Litigation
Company Update / General View filing →
-
6 August 2026 ·
Receipt Of No-Objection Letters From The Stock Exchanges For Reclassification Of Promoter Group
Receipt of No-objection letters from the Stock Exchanges for Reclassification of Promoter Group
Company Update / General View filing →
-
6 August 2026 ·
Earnings Call Transcript
Q1FY27 Earnings Call Transcript
Company Update / Earnings Call Transcript View filing →
-
5 August 2026 ·
Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst/Institutional Investor Meeting
Company Update / Analyst / Investor Meet View filing →
-
5 August 2026 ·
-
31 July 2026 ·
Voting Results And Scrutinizer Report Of 34Th AGM Held On 31 July 2026
Voting Results for 34th AGM
Company Update / General View filing →
-
31 July 2026 ·
Shareholder Meeting / Postal Ballot-Outcome of AGM
Outcome of the 34th Annual General Meeting held on 31 July 2026
AGM/EGM / AGM View filing →
-
31 July 2026 ·
Q1FY27-Investor Call Audio Recording
SPIL Q1FY27-Investor Call Audio Recording
Company Update / General View filing →
-
31 July 2026 ·
Conclusion Of The Board Meeting Held Today, I.E., 31 July 2026
Conclusion of the Board Meeting held today
Company Update / General View filing →
-
31 July 2026 ·
Unaudited Standalone And Consolidated Financial Results For Q1 Of FY 2026-27
Quarterly Financial Results for Q1 of FY 2026-27
Result / Financial Results View filing →
-
29 July 2026 ·
Press Release / Media Release
Sun Pharma receives approval to manufacture and market semaglutide in Brazil
Company Update / Press Release / Media Release View filing →
-
28 July 2026 ·
Newspaper Publication
Newspaper advertisement about opening of Special Window, for transfer of physical shares
Company Update / Newspaper Publication View filing →
-
27 July 2026 ·
-
24 July 2026 ·
Press Release / Media Release
Sun Pharma notes Organon Shareholder approval for proposed acquisition
Company Update / Press Release / Media Release View filing →
RSS feed for Sun Pharmaceutical Industries Ltd · the 50 most recent filings